Amgen awards $350M media account to Hearts & Science after competitive review

Advertising agency word cloud image
Amgen chose Hearts & Science for its strategy, buying and planning work in part because of the agency's data-driven approach. (Alpha Stock Images)

We have a winner: Media agency Hearts & Science has picked up Amgen’s estimated $350 million media account. A competitive review included the retention of Amgen’s HCP business by SSCG, which is one of Hearts & Science Omnicom Media Group's sibling agencies.

Data expertise was key to the victory. Critical factors in the decision were the agency's data-driven approach, more-efficient targeting, innovative approach and capabilities, and ability to expand beyond traditional media channels, a Hearts & Science spokesperson said via email.

RELATED: Sanofi shakes up agency team, adding WPP Group to media and creative partners

The media strategy is estimated to be worth $350 million, according to an Adweek report. Amgen holds scheduled reviews of its agency accounts every three years; this one began in 2016 with two other competitors, Publicis Groupe’s Starcom and WPP’s Wavemaker, in the mix for the account, the report said.

Hearts & Science was launched in 2016 to handle Procter & Gamble’s North American media account after Omnicom won the bulk of that account. P&G is the world’s largest advertiser, spending $10.5 billion annually on advertising and marketing on consumer brands such as Tide, Pampers and Pantene, according to Advertising Age. P&G is also a bit of a rabble rouser in the advertising world, causing industry shifts in priorities and capabilities with its CEO and chief brand officer pronouncements or strategic internal changes.

RELATED: As Eli Lilly moves some marketing in-house, should ad agencies brace for fallout?

Hearts & Science has since added other clients to its stable, including another advertising powerhouse in AT&T, attracting clients with its data-first model. When Hearts & Science launched, Omincom described its third media agency network as “a data-driven marketing agency with expert media planning and buying capabilities, among other services that include shopper marketing, marketing innovation and content activation.”

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.